Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pazopanib + weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma after cisplatin
2014-003127-22Phase 2Terminated
- Sponsor
- SOGUG
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib and paclitaxel in penile squamous cell carcinoma (PSCC), sponsored by SOGUG. Primary endpoint: Objective response rate. Started Nov 2014; status: terminated.
02
Drugs
pazopanibpaclitaxel
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2014-003127-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003127-22.